Quick Facts

• Active Mild-to-Moderate Crohn’s Disease: Indicated for managing episodes of active disease affecting the ileum and/or the ascending colon.
• Maintenance of Clinical Remission: Used for supporting a period of clinical remission in mild-to-moderate Crohn’s disease.

---

Entocort EC (budesonide) is authorized for use in specific therapeutic domains related to Crohn’s disease, a form of inflammatory bowel disease. The medication's principal application is in the management of mild to moderate active Crohn’s disease that involves the ileum and/or the ascending colon, which are sections of the lower digestive tract. This may help in achieving control of active disease symptoms in appropriate patients.

A further important use is in the maintenance of clinical remission following an active episode of mild to moderate Crohn’s disease. In adults, the treatment can be utilized for up to three months to support sustained remission. A healthcare provider determines the full course of treatment.

This application aligns with criteria for its use in patients 8 years of age and older who meet the necessary weight requirements for treatment of active disease.

Official Population Eligibility Profile

Entocort EC eligibility is defined by regulatory bodies based on age, weight, organ function, and specific medical conditions. Use is strictly limited to groups for whom a safety and efficacy profile has been established.

Eligibility Classification	Status and Population
Absolute Contraindication	Patients with known hypersensitivity to budesonide or any excipient in the capsule. Absolute contraindication also applies to patients with rare hereditary problems like fructose intolerance or glucose-galactose malabsorption.
Not Recommended / Avoid Use	Use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) due to the potential for increased systemic exposure. Use should be avoided in patients with active systemic infections, including fungal, bacterial, or viral diseases, and active tuberculosis.
Age-Related Eligibility	Adults are eligible for labeled uses. Pediatric use is restricted to patients 8 years of age and older who weigh more than 25 kg. Safety and effectiveness are not established for children younger than 8 years or those weighing 25 kg or less.
Conditional Use	Use requires caution and monitoring in patients with moderate hepatic impairment (Child-Pugh Class B). Caution is also advised for patients with existing conditions such as hypertension, diabetes mellitus, peptic ulcer, glaucoma, or osteoporosis.

Pregnancy and Lactation Status The medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. For breastfeeding individuals, regulatory guidance advises a decision to discontinue either nursing or the drug.

Connection to the overall eligibility profile Regulatory documents establish eligibility by identifying populations who are explicitly prohibited (contraindicated) and those for whom use is restricted or limited due to factors such as physiological maturity, compromised liver function, or the presence of underlying infection risks.

Entocort EC (budesonide) is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. This metabolic route is the primary basis for its drug interactions.

Clinically Significant Interactions

Interacting Product Category	Effect and Precaution
Strong CYP3A4 Inhibitors (e.g., ketoconazole)	Can substantially increase the systemic concentration of budesonide, raising the risk of hypercorticism and adrenal axis suppression. Avoid co-administration.
Grapefruit Juice	Inhibits intestinal CYP3A, which can approximately double systemic budesonide exposure. Avoid consumption for the duration of therapy.
CYP3A4 Inducers (e.g., carbamazepine)	Can increase the breakdown of budesonide, potentially leading to lower blood levels and reduced therapeutic effect. Avoid or use an alternative medicine.
Live Vaccines (e.g., BCG)	Corticosteroids can suppress the immune system, increasing the risk of infection and disseminated disease from live vaccines. These combinations are generally contraindicated.

When transferring a patient from a systemic corticosteroid like oral prednisolone, the previous steroid must be tapered gradually while initiating Entocort EC. Patients with moderate to severe hepatic impairment may experience reduced clearance of budesonide, potentially requiring a dosage adjustment.

Targeting the Glucocorticoid Receptor for Genomic Reprogramming

The drug's action begins at the cellular level by acting as a synthetic ligand for the intracellular Glucocorticoid Receptor (GR). This interaction leads to genomic reprogramming, simultaneously blocking pro-inflammatory genetic signals (Transrepression) from factors like NF-kappaB while promoting the synthesis of anti-inflammatory proteins (Transactivation). This fundamental shift in gene expression is the core mechanism that determines the resulting anti-inflammatory action.

---

Pathway Suppression to Limit Inflammatory Mediators

The anti-inflammatory proteins produced through genomic action, such as Lipocortin-1, initiate a cascade that leads to the functional inhibition of the enzyme Phospholipase A2 (PLA2). By inhibiting PLA2, the mechanism reduces the synthesis of inflammatory mediators like prostaglandins and leukotrienes. This pathway suppression results in reduced immune cell infiltration and decreased vascular permeability at the tissue level, influencing the localized fluid balance (edema) in the intestinal lining.

---

Anatomical Localization and Constrained Mechanism

The mechanism is uniquely constrained to the ileum and ascending colon due to the specialized extended-release formulation. This localization ensures the high-affinity Glucocorticoid Receptor agonism is delivered directly to the target tissue, concentrating its anti-inflammatory action to the localized area. This constraint allows the drug to exert its high-affinity action on localized inflammatory pathways while minimizing its influence on other systemic physiological processes.

Entocort EC is a delayed-release capsule intended for oral administration. The medication is administered once daily, typically taken in the morning to maintain a consistent dosing interval. Proper administration is crucial due to the capsule's specialized design; the capsules must be swallowed whole and must not be chewed, crushed, or broken. This instruction is designed to ensure the medicine is delivered locally to the lower intestine. If the capsule cannot be swallowed, the contents may be mixed with applesauce and consumed immediately, provided the granules themselves are not crushed.

The standard dosing regimen for adults is determined by the treatment phase. For the induction of remission in active disease, the prescribed dose is generally 9 mg once daily for a course duration of up to eight weeks. For the maintenance of clinical remission, the standard dose is 6 mg once daily for a course of up to three months. Upon completion of the time-limited course, a gradual tapering of the dose is required prior to cessation.

Specific usage rules apply to certain populations. For pediatric patients aged 8 to 17 years who weigh more than 25 kg, the active disease course begins with 9 mg daily, followed by a reduction to 6 mg daily for two weeks. Patients with moderate hepatic impairment may require a dose adjustment to 3 mg once daily, and the medication is not recommended for use in severe hepatic impairment. The administration guidelines also specify the avoidance of grapefruit juice for the duration of therapy.

Research Evidence / Overview of Studies for Entocort EC

Evidence for Use in Active Mild-to-Moderate Crohn’s Disease

Research exploring the use of Entocort EC for active Crohn’s disease explores its use in the specific context where inflammation was primarily located in the lower parts of the digestive tract, such as the ileum or ascending colon. This area has been studied using short-term Randomized Controlled Trials (RCTs). These studies are designed exploring symptom measurements over defined time intervals, typically 8 to 12 weeks, by comparing the agent to an inactive placebo or, in some cases, an active comparator. Researchers monitored outcomes mainly looking at the rate at which patients achieved clinical remission (a specific measurement indicating low disease activity).

The short-term trials reported measurements where a certain percentage of the observed patient groups achieved clinical remission within the study period. Studies described measurements of lower rates of achieving remission compared to those with milder activity levels. The results apply only to the populations studied and only cover the short induction period. There is limited information for long-term outcomes related to disease progression beyond the initial 12 weeks.

Evidence for Maintenance of Clinical Remission

The evidence base includes research exploring whether Entocort EC helps to support a stable period after a flare-up. This research comes from RCTs that focused on outcomes related to prevention of relapse in adults who had already achieved remission. Studies explored measurements of the agent compared to a placebo. Studies reported measurements of sustained remission rates for periods of up to three months, which aligns with the authorized use. However, when research was extended to look at longer-term observation periods, such as 6 to 12 months, the findings were mixed. The data collected for durability of response past the initial few months described variability across the broader evidence landscape.

It is not yet clear whether research describes a reliable means to support long-term remission beyond the 3-month period. Certainty remains low for these extended periods because studies have reported considerable variability. The research primarily focuses on mild-to-moderate disease activity, and comparative evidence is lacking for managing more severe disease.

Key Studies & References

1. Clinical Trials Summary for Budesonide in Mild-to-Moderate Active Crohn's Disease (focusing on CDAI outcomes)

Common questions about Entocort EC (FAQ)

---

Q: How long does it usually take to notice any effect from Entocort EC?

A: Official information describes that the drug is formulated to deliver the active ingredient to the target area shortly after leaving the stomach. The active substance typically reaches its maximum concentration in the blood around 3 hours after administration. Clinical studies designed to measure full remission or improvement usually evaluate the medicine's effects over a period of 8 to 12 weeks of treatment.

Q: Can Entocort EC be taken long-term?

A: Official documents indicate that this medication is used for a limited period, typically up to 8 weeks for active disease and up to 3 months for maintaining remission. Research indicates that continued treatment beyond the authorized three-month period has not been shown to provide substantial additional benefit.

Q: What are the typical gastrointestinal side effects associated with Entocort EC?

A: As documented in official product information, common gastrointestinal side effects reported in clinical trials include nausea, abdominal pain, indigestion (dyspepsia), vomiting, and flatulence. These are some of the most frequently observed effects in adult patients receiving the treatment.

Q: Can Entocort EC cause mood changes or sleep problems?

A: Yes, official regulatory safety lists document that psychological effects such as mood changes (mood swings) and sleep problems, specifically insomnia, are common adverse reactions associated with this medicine. These effects are related to the glucocorticoid class of drugs.

Q: Does taking Entocort EC affect blood sugar levels?

A: As a glucocorticoid, the medicine may cause an increase in blood sugar levels. For this reason, official labeling advises caution for patients who have pre-existing conditions like diabetes mellitus.

Q: Can Entocort EC be taken if I have liver problems?

A: Regulatory information states that use is not recommended for individuals with severe hepatic impairment (liver damage). Caution and monitoring are advised for those with moderate hepatic impairment because slower drug removal from the body may increase its systemic exposure.

Q: Is it possible to become dependent on Entocort EC?

A: Official warnings indicate that the medicine can cause adrenal axis suppression, which involves a reduction in the body's natural cortisol production. Stopping the medication abruptly, especially after prolonged use, may lead to symptoms related to steroid withdrawal, which is why a gradual dose reduction is required.

Q: What happens if I forget to take a dose of Entocort EC?

A: According to official patient information, if a dose is missed, it should be taken as soon as the individual remembers it. However, if it is almost time for the next scheduled dose, the missed dose should generally be skipped, and the individual should resume the regular schedule, avoiding double doses.

Q: Does Entocort EC make you gain weight?

A: Regulatory adverse event data includes weight gain as a reported side effect. The medicine can also potentially lead to systemic effects such as hypercorticism, which is a condition associated with changes like fat redistribution or fluid retention.

Q: How is Entocort EC different from the rectal foam version of budesonide?

A: The primary difference lies in the area of the intestine that is targeted. Entocort EC capsules are specially formulated to deliver the medicine to the ileum and ascending colon, while the rectal foam or suppository formulations are intended for localized action in the lower colon and rectum.

Q: What happens if Entocort EC doesn't seem to be working?

A: Official patient information advises individuals to consult with their healthcare team for regular progress checks while taking the medicine. It is important to report if symptoms do not begin to improve within the expected timeframe or if they worsen.

Q: Do children use Entocort EC for inflammatory bowel disease?

A: Yes, the official regulatory approval includes pediatric patients. The medicine is indicated for children 8 years of age and older who weigh more than 25 kg for the treatment of mild to moderate active Crohn’s disease in the targeted parts of the colon.

Q: What are the most common reasons a doctor prescribes Entocort EC?

A: The regulatory indications for this medicine are specific to Crohn's disease. It is officially approved for the treatment of mild to moderate active Crohn's disease and for the maintenance of clinical remission of mild to moderate Crohn's disease, involving the ileum and/or the ascending colon.

Q: What are the official regulatory approvals for Entocort EC?

A: Regulatory bodies have approved this medicine for two specific uses: treating a flare-up of mild to moderate active Crohn's disease and supporting the maintenance of remission in mild to moderate Crohn's disease. These approvals apply to disease involving the ileum and/or the ascending colon.

Q: If I have a history of depression, are there special considerations for using Entocort EC?

A: Official labeling advises caution for patients with pre-existing conditions where corticosteroids may have undesirable effects. The medicine is documented to cause psychological changes, and mood swings are listed as a common adverse reaction.

Q: Does Entocort EC interact with birth control pills?

A: Official interaction studies indicate that oral contraceptives containing ethinyl estradiol do not appear to affect the body's processing of budesonide. Likewise, budesonide does not appear to affect the plasma levels of these specific types of oral contraceptives.

Q: Is Entocort EC used for conditions other than Crohn's disease?

A: The specific Entocort EC capsule formulation is indicated by regulatory bodies only for the treatment and maintenance of mild to moderate Crohn's disease involving the ileum and/or the ascending colon.

Storage and Disposal Requirements

Entocort EC capsules must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required to keep the medication out of the reach and sight of children. To maintain product integrity, the capsules must be kept from freezing and protected from light and moisture.

Keep the medicine in the original container with the lid tightly closed.

Disposal

Official labeling directs that unused or expired Entocort EC must be disposed of safely; patients should consult a pharmacist or healthcare professional for instructions. The medication should not be flushed down a toilet or discarded in a drain. If a capsule is opened and mixed with applesauce, any unused portion of the mixture must be discarded after 30 minutes.